TITLE

Continued Opportunities Exist for FDA and OPM to Improve Oversight of Recruitment, Relocation, and Retention Incentives

AUTHOR(S)
Goldenkoff, Robert N.
PUB. DATE
February 2010
SOURCE
GAO Reports;2/22/2010, preceding p1
SOURCE TYPE
Government Document
DOC. TYPE
Article
ABSTRACT
The article presents a study done by the United States Accountability Office (GAO) which aims to know the extent to which the Food and Drug Administration (FDA) is linking its use of employee recruitment, relocation and retention (3R) incentives to its human capital approaches in addressing challenges. It explores the extent of the 3R incentive regulations. It details the steps the Office of Personnel Management (OPM) take to help ensure effective supervision of the 3R incentive programs.
ACCESSION #
48811738

 

Related Articles

  • OLDER WORKERS Enhanced Communication among Federal Agencies Could Improve Strategies for Hiring and Retaining Experienced Workers. Bovbjerg, Barbara D.; Goldenkoff, Robert N. // GAO Reports;2/27/2009, preceding p1 

    The article presents a report from the Government Accountability Office (GAO) in the U.S. regarding the eligibility of the federal workforce to retire. It highlights the anticipation that such condition will leave behind gaps in leadership, skills and knowledge due to slower growing pool of...

  • VETERINARIAN WORKFORCE The Federal Government Lacks a Comprehensive Understanding of Its Capacity to Protect Animal and Public Health.  // GAO Reports;2/27/2009, preceding p1 

    The article presents a report from the Government Accountability Office (GAO) in the U.S. regarding the failure of the government to understand its capacity in protecting the animal and public health. It highlights the need for the Office of Personnel Management (OPM) to use its leadership...

  • FDA Update.  // Pharmaceutical Representative;May2010, Vol. 40 Issue 5, p11 

    The article focuses on a report issued by the U.S. Government Accountability Office (GAO) concerning the strategic planning and management of the Food and Drug Administration (FDA).

  • WEEK IN WASHINGTON.  // BioWorld Insight;2/18/2014, Vol. 22 Issue 7, p6 

    The article offers information on the role of the U.S. Food and Drug Administration for missing out the opportunities to mitigate and proactively prevent drug shortages in the U.S., according to the reports of the U.S. Government Accountability Office (GAO).

  • FDA safety effort necessary.  // Medical Marketing & Media;Feb2010, Vol. 45 Issue 2, p10 

    The article reports on the U.S. Government Accountability Office (GAO) study on the need for the Food and Drug Administration (FDA) to develop a comprehensive plan to prepare the Office of Surveillance and Epidemiology (OSE) to take over additional regulatory authorities from the Office of New...

  • FDA Questioned by Other Feds on High-Risk Devices. Reed, Vita // Orange County Business Journal;4/25/2011, Vol. 34 Issue 17, p65 

    The article reports that the approval of U.S. Food and Drug Administration (FDA) to certain high-risk medical devices such as pacemakers and hip joints, has been criticized by the Government Accountability Office (GAO), which states that the high-risk devices are approved without sufficient...

  • DRUG SAFETY: FDA Has Begun Efforts to Enhance Postmarket Safety, but Additional Actions Are Needed.  // GAO Reports;12/9/2009, preceding p1 

    The article discusses the findings of the U.S. Government Accountability Office (GAO) on the oversight of postmarket drug safety by the Food and Drug Administration (FDA). GAO claims that FDA has started to address concerns in its postmarket drug safety management. GAO also admires FDA's move to...

  • FOOD SAFETY: FDA Should Strengthen Its Oversight of Food Ingredients Determined to Be Generally Recognized as Safe (GRAS). Shames, Lisa // GAO Reports;3/5/2010, preceding p1 

    The article examines the oversight of the U.S. Food and Drug Administration on generally recognized as safe (GRAS) substances, by the Government Accountability Office (GAO). It was found that its oversight process does not ensure the safety of GRAS determinations. The agency does not issue...

  • New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts: GAO-07-49. Aronovitz, Leslie G. // GAO Reports;12/19/2006, p1 

    Drug development is complex and costly, requiring the testing of numerous chemical compounds for their potential to treat disease. Before a new drug can be marketed in the United States, a new drug application (NDA), which includes scientific and clinical data, must be approved by the Food and...

Share

Read the Article

Other Topics